The Focus for Pharmaceutical Knowledge: The Proceedings of the Sixth International Meeting of Pharmaceutical Physicians Brighton, England, June 1987

Front Matter....Pages i-xvi
Quality of life....Pages 1-10
Contributions of the pharmaceutical industry to health care....Pages 11-15
Failings of the pharmaceutical industry....Pages 16-22
Improving health care by improving the image of the pharmaceutical industry....Pages 23-27
General discussion on pharmaceuticals and health care....Pages 28-37
The future of the pharmaceutical industry....Pages 38-45
Genes, monoclonal antibodies and cancer....Pages 46-52
Development of biological agents through DNA technology....Pages 53-65
Creating a comprehensive and accurate database of efficacy and safety information....Pages 66-72
Who needs good clinical practice?....Pages 73-75
Checks expected by regulatory authorities....Pages 76-82
Good clinical practice....Pages 83-88
Clinical pharmacology in industry....Pages 89-94
Multicentre trials in drug development: good? necessary?....Pages 95-101
Phase IV studies: experience in Spain....Pages 102-106
Influence of methodology on the results of phase IV studies....Pages 107-114
Phase IV: the opportunity and the challenge....Pages 115-118
Concordance of clinical and marketing objectives in phase IV....Pages 119-125
Exploring the clinical properties of marketed drugs....Pages 126-135
Post-marketing surveillance....Pages 136-159
US initiatives in post-marketing drug surveillance....Pages 160-167
Dosage adjustment needed in developing countries....Pages 168-177
Developing countries and their rôle in new drug development: a south-east Asian perspective....Pages 178-186
Clinical trials in parasitic diseases: measurements, controls and ethics....Pages 187-193
Feasibility and credibility of a local R&D programme in Africa....Pages 194-200
Geographical, genetic and environmental factors affecting drug disposition....Pages 201-207
Drug development in the elderly: problems and constraints....Pages 208-221
Problems in infancy and childhood....Pages 222-229
Orphan drugs—or orphan diseases?....Pages 230-238
Ethics....Pages 239-244
Obtaining consent in ‘special’ populations....Pages 245-249
Compensation: responsibilities of the industry to the patient....Pages 250-253
Information for the consumer in the United Kingdom....Pages 254-259
Drugs and information for the public in France....Pages 260-266
Information for the consumer in the USA....Pages 267-271
Re-registration of drugs in the 1990s....Pages 272-275
Regulatory requirements in the UK in the 1990s....Pages 276-279
Drug regulation in the future from the point of view of the industry....Pages 280-285
Consolidating the discipline of pharmaceutical medicine in the United Kingdom....Pages 286-292
A customized game as an aid for medical representative training....Pages 293-299
Sponsored meetings and publications: a round-table discussion....Pages 300-309
Back Matter....Pages 311-315